1 / 32

MALIGNANT PLEURAL MESOTHELIOMA

MALIGNANT PLEURAL MESOTHELIOMA. Giovanni Luca Ceresoli Humanitas Gavazzeni Bergamo. Unmet needs in MPM. Role of surgery and radiotherapy (IMRT) How to improve results of first-line treatments Role of second-line treatments Response radiological assessment

elon
Download Presentation

MALIGNANT PLEURAL MESOTHELIOMA

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MALIGNANT PLEURAL MESOTHELIOMA Giovanni Luca Ceresoli HumanitasGavazzeni Bergamo POST IASLC Milano 8 NOV 2013

  2. Unmet needs in MPM • Role of surgery and radiotherapy (IMRT) • How to improve results of first-line treatments • Role of second-line treatments • Response radiological assessment • Better understanding of the biology of the disease POST IASLC Milano 8 NOV 2013

  3. MPM in WCLC 2013 1 Abstract presented during Plenary Session 1 Oral Abstract Session 2 Mini Oral Abstract Sessions 3 Poster Sessions 2 Mini-Simposia 5 MTE Sessions SURGERY & MULTIMODALITY TREATMENTS SECOND-LINE TREATMENTS RESPONSE EVALUATION BIOLOGY POST IASLC Milano 8 NOV 2013

  4. Role of surgery (P/D vs EPP) Non surgical group imbalanced: older than surgical pts, less epithelioid, less treated with chemotherapy P/D nothomogeneous (different centers, 30-yr span) 1227 evaluablepts, from 1982 to 2012 in 6 Institutions Bille et al., WCLC 2013 POST IASLC Milano 8 NOV 2013

  5. Role of surgery (P/D vs EPP) (age <70 yrs, epitheliodtype, chemotherapy) 313 pts with favorableprognosticfactors (25%) Bille et al., WCLC 2013 POST IASLC Milano 8 NOV 2013

  6. P/D in MPM: different techniques IMIG/IASLC consensus, JTO 2011; Cao et al., WCLC 2013 POST IASLC Milano 8 NOV 2013

  7. 175 patients Primaryendpoint: 1-yr OS; secondaryendpoints: QoL, control of pleuraleffusion Rintoul et al., WCLC 2013 POST IASLC Milano 8 NOV 2013

  8. The mesoVATs trial: survival Rintoul et al., WCLC 2013 POST IASLC Milano 8 NOV 2013

  9. The mesoVATs trial: QoL & pleural effusion control • No difference in overall survival; • P/D has a modest advantage in QoL and effusion control; • P/D: more toxicities & lenght of stay in hospital, more expensive. Rintoul et al., WCLC 2013 POST IASLC Milano 8 NOV 2013

  10. Hemithoracic pleural IMRT after P/D 20 pts have completed RT, 1 is on treatment. 5 pts with grade 2 RP, 1 grade 3; early intervention with steroids effective in controlling RP. Wu et al., WCLC 2013 POST IASLC Milano 8 NOV 2013

  11. PI3K/mTOR INHIBITORS IN SECOND-LINE SETTING IN MPM GDC 0980, 30 mg orallydaily Phase I + MPM expandedcohortat P2RD Overall 33 pts; 4 PR, RR 12% PI3K mutations and pTENlossuncommon Dolly et al., WCLC 2013 POST IASLC Milano 8 NOV 2013

  12. POST IASLC Milano 8 NOV 2013

  13. POST IASLC Milano 8 NOV 2013

  14. Hassan et al., WCLC 2013 POST IASLC Milano 8 NOV 2013

  15. Hassan et al., WCLC 2013 POST IASLC Milano 8 NOV 2013

  16. Hassan et al., WCLC 2013 POST IASLC Milano 8 NOV 2013

  17. SS1P plus PC in MPM Hassan et al., WCLC 2013 POST IASLC Milano 8 NOV 2013

  18. SS1P plus PC in MPM Hassan et al., WCLC 2013 POST IASLC Milano 8 NOV 2013

  19. VINORELBINE and BRCA1 in MPM Sensitivity to vinorelbine correlates with BRCA1 expression in 6 mesothelioma cell lines. 38.9 % 61.1 % Busacca et al., J Pathol 2012 9 POST IASLC Milano 8 NOV 2013

  20. VINORELBINE and BRCA1 in MPM Randomised phase II trial of oral vinorelbine as second-line therapy for patients with MPM expressing BRCA1 – VIM trial Weeklyoral VINORELBINE + ASC Relapsed MPM R ASC (activesymptom control) 2:1 BRCA1 expression IHC will be evaluatedas a stratificationfactor. Primaryendpoint: overallsurvival. 114 participantsrequired (76 VNR, 38 ASC) Fennell et al., Poster Session 2 Mesothelioma, P2.14-013 9 POST IASLC Milano 8 NOV 2013

  21. Tremelimumab: an anti-CTLA-4 mAb • Tremelimumab (CP675,206)Pfizer/MedImmuneIgG2 isotypeantibodyhalf-life time: 22 days T-cellcostimulatoryreceptors T-cell potentiation T cell CTLA-4 TCR CTLA-4 mAb B7 MHC APC POST IASLC Milano 8 NOV 2013

  22. Immunotherapy in MPM: tremelimumab Calabrò et al., Lancet Oncol 2013 POST IASLC Milano 8 NOV 2013

  23. Randomized TREMELIMUMAB: PLACEBO 2:1 (120/60) Stratification Factors European Organization for Research and Treatment of Cancer (EORTC) status (low-risk vs high-risk) Line of therapy (second vs third) Anatomical site (pleural vs peritoneal) Treme 10mg/kg Q12Wk (Non Dosing visits: V9, 11, 13) Treme 10mg/kg Q4Wk x 6 doses Relapsed/Refractory Malignant Mesothelioma (2nd/3rd line) Total recruitment = 180 patients (OS events) Placebo Q12Wk (Non Dosing visits: V9, 11, 13) Placebo Q4Wk x 6 doses Phase II Multicenter, International, Randomized Trial of Tremelimumab in Patients With Unresectable Mesothelioma (Trial D4880C00003 Sponsored by MedImmune) 2:1 Primaryendpoint: OS NCT01843374 Kindler et al., Poster Session 2 Mesothelioma, P2.14-015 23 POST IASLC Milano 8 NOV 2013

  24. Focal adhesion kinases (FAK) inhibitors in MPM • Pemetrexed and cisplatin increase cancer stem cells (CSCs). • FAK inhibitors decrease CSCs in mesothelioma models. • NF2 tumor suppressor gene is inactivated in 40-50% of MPM pts, resulting in lack of expression of functional Merlin protein. • Mesothelioma cells that lack NF2/Merlin are especially sensitive to FAK inhibitors. Poulikakos et al., Oncogene 2006 POST IASLC Milano 8 NOV 2013

  25. Focal adhesion kinases (FAK) inhibitors in MPM: VS-6063 1:1 (or Carbo/Cis) PrimaryEndpoint: PFS Approx. 370 ptsincluded Keegan et al., Poster Session 2 Mesothelioma, P2.14-014 POST IASLC Milano 8 NOV 2013

  26. Volumetric CT tumor response in MPM Armato et al., WCLC 2013 POST IASLC Milano 8 NOV 2013

  27. Volumetric CT tumor response in MPM Semi-automated method to determine MPM volume from CT scans retrospectively collected from 70 patients undergoing standard of care chemotherapy. Armato et al., WCLC 2013 POST IASLC Milano 8 NOV 2013

  28. Volumetric CT tumor response in MPM 41 consecutive radical P/D • CONCLUSIONS • OS and PFS were correlated with tumor volume (TV). • All radiographic techniques underestimated actual TV. • Estimates closer to actual TV as they became less automated and more manual. Friedberg et al., WCLC 2013 POST IASLC Milano 8 NOV 2013

  29. Gene sequencing CDKN2A, NF2 and BAP1 are the mostfrequentlymutatedgenes in MPM POST IASLC Milano 8 NOV 2013

  30. BAP-1 SYNDROME UVEAL MELANOMA MALIGNANT MESOTHELIOMA MELANOCYTIC BAP-1 MUTATED ATYPICAL INTRADERMAL TUMOURS CUTANEOUS MELANOMA Carbone et al., WCLC 2013 POST IASLC Milano 8 NOV 2013

  31. Tissue microarray from 170 epithelioid MPM, MSKCC Ujiiee et al., WCLC 2013 POST IASLC Milano 8 NOV 2013

  32. Conclusions • The debate on surgery in MPM continues: expanding role of P/D, mesoVATs. • IMRT after P/D or no surgery. • Medical treatment: SS1P plus PC promising; new options/studies: BRCA1/vinorelbine, tremelimumab, FAK-inhibitors. • Volumetric CT response evaluation: pitfalls and challanges. • Biology: gene sequencing, BAP1 syndrome. Role of the immune system. POST IASLC Milano 8 NOV 2013

More Related